Get started
BridgeBio Pharma, Inc.BridgeBio Pharma, Inc.BridgeBio Pharma, Inc.

BridgeBio Pharma, Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals Bonds

BBIO chart


Full chart

BBIO upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪5.01 B‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−2.41 USD
Net income (FY)
‪−643.20 M‬ USD
Revenue (FY)
‪9.30 M‬ USD
Shares float
‪147.70 M‬
Beta (1Y)
0.65

Employees


Employees (FY)
550
Change (1Y)
+154 +38.89%
Revenue / Employee (1Y)
‪16.91 K‬ USD
Net income / Employee (1Y)
‪−1.17 M‬ USD

About BridgeBio Pharma, Inc.


Sector
Health Technology
Industry
Biotechnology
CEO
Neil Kumar
Website
bridgebio.com
Headquarters
Palo Alto
Founded
2015
FIGI
BBG00P9KDZK6
BridgeBio Pharma, Inc. engages in identifying and advancing transformative medicines to treat patients who suffer from Mendelian diseases. Its pipeline of development programs includes product candidates ranging from early discovery to late-stage development. The company was founded by Charles Homcy, Frank McCormick, Philip Reilly, and Neil Kumar in 2015 and is headquartered in Palo Alto, CA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

BBIO news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

BBIO highest yielding bonds


BBIO5355568
BridgeBio Pharma, Inc. 2.25% 01-FEB-2029
Yield to maturity
6.95%
Maturity date
Feb 1, 2029
BBIO5151039
BridgeBio Pharma, Inc. 2.5% 15-MAR-2027
Yield to maturity
0.73%
Maturity date
Mar 15, 2027

Explore more bonds 

Frequently Asked Questions


The current price of BBIO is 26.49 USD — it has increased by 1.07% in the past 24 hours. Watch BridgeBio Pharma, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange BridgeBio Pharma, Inc. stocks are traded under the ticker BBIO.
BBIO stock has fallen by −4.30% compared to the previous week, the month change is a 18.15% rise, over the last year BridgeBio Pharma, Inc. has showed a −31.18% decrease.
We've gathered analysts' opinions on BridgeBio Pharma, Inc. future price: according to them, BBIO price has a max estimate of 70.00 USD and a min estimate of 37.00 USD. Watch BBIO chart and read a more detailed BridgeBio Pharma, Inc. stock forecast: see what analysts think of BridgeBio Pharma, Inc. and suggest that you do with its stocks.
BBIO reached its all-time high on Feb 9, 2021 with the price of 73.50 USD, and its all-time low was 4.98 USD and was reached on May 12, 2022. View more price dynamics on BBIO chart.
See other stocks reaching their highest and lowest prices.
BBIO stock is 3.38% volatile and has beta coefficient of 0.65. Track BridgeBio Pharma, Inc. stock price on the chart and check out the list of the most volatile stocks — is BridgeBio Pharma, Inc. there?
Today BridgeBio Pharma, Inc. has the market capitalization of ‪5.01 B‬, it has decreased by −4.00% over the last week.
Yes, you can track BridgeBio Pharma, Inc. financials in yearly and quarterly reports right on TradingView.
BridgeBio Pharma, Inc. is going to release the next earnings report on Feb 20, 2025. Keep track of upcoming events with our Earnings Calendar.
BBIO earnings for the last quarter are −0.86 USD per share, whereas the estimation was −1.00 USD resulting in a 14.28% surprise. The estimated earnings for the next quarter are −1.13 USD per share. See more details about BridgeBio Pharma, Inc. earnings.
BridgeBio Pharma, Inc. revenue for the last quarter amounts to ‪2.73 M‬ USD, despite the estimated figure of ‪1.68 M‬ USD. In the next quarter, revenue is expected to reach ‪3.26 M‬ USD.
BBIO net income for the last quarter is ‪−162.04 M‬ USD, while the quarter before that showed ‪−73.46 M‬ USD of net income which accounts for −120.59% change. Track more BridgeBio Pharma, Inc. financial stats to get the full picture.
No, BBIO doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 21, 2024, the company has 550.00 employees. See our rating of the largest employees — is BridgeBio Pharma, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. BridgeBio Pharma, Inc. EBITDA is ‪−526.40 M‬ USD, and current EBITDA margin is ‪−6.37 K‬%. See more stats in BridgeBio Pharma, Inc. financial statements.
Like other stocks, BBIO shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade BridgeBio Pharma, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So BridgeBio Pharma, Inc. technincal analysis shows the sell today, and its 1 week rating is neutral. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating BridgeBio Pharma, Inc. stock shows the sell signal. See more of BridgeBio Pharma, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.